Saravanakumar Marimuthu
Overview
Explore the profile of Saravanakumar Marimuthu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogunleye A, Gayen N, Rauth S, Marimuthu S, Nimmakayala R, Alsafwani Z, et al.
Cancer Metab
. 2024 Sep;
12(1):26.
PMID: 39242538
Background: PAF1/PD2 deregulation contributes to tumorigenesis, drug resistance, and cancer stem cell maintenance in Pancreatic Cancer (PC). Recent studies demonstrate that metabolic reprogramming plays a role in PC progression, but...
2.
Ramalho de Lima M, Kaneko I, de Lima A, de Melo L, de Lima M, de Brito A, et al.
PLoS One
. 2024 Mar;
19(3):e0295488.
PMID: 38502648
This study was carried out to compare the impact of choline supplementation (available from two sources synthetic and natural) on various dosages in broilers. The mode of choline supplementation, via...
3.
Shah A, Chaudhary S, Lakshmanan I, Aithal A, Kisling S, Sorrell C, et al.
NPJ Precis Oncol
. 2023 Aug;
7(1):74.
PMID: 37567918
Aberrantly expressed onco-mucin 16 (MUC16) and its post-cleavage generated surface tethered carboxy-terminal (MUC16-Cter) domain are strongly associated with poor prognosis and lethality of pancreatic (PC) and non-small cell lung cancer...
4.
Chaudhary S, Appadurai M, Maurya S, Nallasamy P, Marimuthu S, Shah A, et al.
Breast Cancer Res
. 2023 Mar;
25(1):25.
PMID: 36918912
Background: Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targeted...
5.
Marimuthu S, Suresh S, DSouza P
J Adv Vet Anim Res
. 2022 Nov;
9(3):432-439.
PMID: 36382045
Objective: To elucidate the cellular mechanisms of polyherbal formulation [Kolin Plus (KP)], genomics was performed to delineate the genes and pathways associated with lipid regulation through transcriptional profiling of the...
6.
Zhang C, Atri P, Nallasamy P, Parte S, Rauth S, Nimmakayala R, et al.
Cancer Lett
. 2022 Oct;
551:215922.
PMID: 36285687
Mucin MUC4 is an aberrantly expressed oncogene in pancreatic ductal adenocarcinoma (PDAC), yet no pharmacological inhibitors have been identified to target MUC4. Here, we adapted an in silico screening method...
7.
Lakshmanan I, Marimuthu S, Chaudhary S, Seshacharyulu P, Rachagani S, Muniyan S, et al.
Oncogene
. 2022 Oct;
41(48):5147-5159.
PMID: 36271032
MUC16, membrane-bound mucin, plays an oncogenic role in pancreatic ductal adenocarcinoma (PDAC). However, the pathological role of MUC16 in the PDAC progression, tumor microenvironment, and metastasis in cooperation with Kras...
8.
Marimuthu S, Batra S, Ponnusamy M
Clin Transl Discov
. 2022 Jul;
2(2).
PMID: 35875597
No abstract available.
9.
Marimuthu S, Lakshmanan I, Muniyan S, Gautam S, Nimmakayala R, Rauth S, et al.
Mol Cancer Res
. 2022 May;
20(8):1208-1221.
PMID: 35533267
Implications: This study shows that MUC16 plays a critical role in PDAC liver metastasis by mediating NRP2 regulation by JAK2/STAT1 axis, thereby paving the way for future therapy efforts for...
10.
Nimmakayala R, Rauth S, Chirravuri Venkata R, Marimuthu S, Nallasamy P, Vengoji R, et al.
Clin Cancer Res
. 2021 Jun;
27(19):5415-5429.
PMID: 34172498
Purpose: Metabolic reprogramming and cancer stem cells drive the aggressiveness of pancreatic ductal adenocarcinoma (PDAC). However, the metabolic and stemness programs of pancreatic precursor lesions (PPL), considered early PDAC development...